Remove Asset Management Remove DCF Remove Definition
article thumbnail

Long-Only Hedge Funds: A Cozy Career, or a Complete Contradiction?

Mergers and Inquisitions

And if you are interested in this strategy, should you even target hedge funds, or would a long-only asset management firm be better? I’ll answer both questions here, but I want to start with a few definitions: What is a Long-Only Hedge Fund? This second trade would be much less likely at a long-only asset management firm.

Funds 52
article thumbnail

Equity Research vs. Investment Banking: Careers, Compensation, Exits, and AI/Automation Risk

Mergers and Inquisitions

For example, in IB interviews, youll have to know about accounting, valuation/DCF analysis, merger models, and LBO models plus the usual fit/behavioral questions , your resume walkthrough , and a few recent deals. public markets roles ( hedge funds , asset management , etc.), bulge bracket research team to startup PE firm).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Multi-Manager Hedge Funds: A Meritocratic Paradise or a Revolving Door of Burnout?

Mergers and Inquisitions

So, expect a lot of quarterly financial projections , quick public comps , and simple DCF models linked to specific catalysts. Do Multi-Manager Hedge Funds Deliver? Multi-manager hedge funds have been in the news because they’ve performed better and grown more quickly than the larger hedge fund universe.

Funds 104
article thumbnail

Sovereign Wealth Funds: The Full Guide to the Industry, Recruiting, Careers, and Exits

Mergers and Inquisitions

I’ll address all these points here and cover the advantages and disadvantages of SWFs, but let’s start with the definitions and overview: What Are Sovereign Wealth Funds? Some SWFs operate like long-only asset managers (i.e.,

article thumbnail

Biotech Hedge Funds: A Match Made in Heaven

Mergers and Inquisitions

Biotech Hedge Funds Definition: Biotech hedge funds bet for or against public biopharmaceutical companies, typically based on catalysts such as clinical trial results, acquisitions, and liquidations; many funds focus on early-stage companies, but some also invest in platform companies, and some also make private-market investments.

Funds 64